<DOC>
	<DOCNO>NCT02319486</DOCNO>
	<brief_summary>This study evaluate uniform chemotherapy protocol nonmetastatic extraocular retinoblastoma</brief_summary>
	<brief_title>CEV With/Without Periocular Carboplatin Chemotherapy Extraocular Retinoblastoma</brief_title>
	<detailed_description>This study phase 4 open label interventional case series . Patients retinoblastoma receive chemotherapy without periocular injection carboplatin dose 20mg/2 ml . Patients receive chemotherapy monthly basis total duration therapy 6 month . Patients follow 18 month .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>IRSS stage II stage IIIa RB patient . patient IRSS stage II disease , scleral surface invasion alone observe , systemic chemotherapy administer , whereas IRSS stage II IIIa patient receive systemic chemotherapy plus additional local chemotherapy . tumorrelated treatment give prior chemotherapy regimen . metastasis , include lymph node metastasis . diagnosis IRSS stage I nontarget eye .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Retinoblastoma</keyword>
	<keyword>carboplatin</keyword>
</DOC>